MA vs. GSK.L
MA (Mastercard Incorporated) and GSK.L (GlaxoSmithKline plc) are both stocks. MA operates in Credit Services (Financial Services), while GSK.L operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, MA returned 18.40%/yr vs 4.80%/yr for GSK.L. At a 0.21 correlation, their price movements are largely independent.
Performance
MA vs. GSK.L - Performance Comparison
Loading charts...
Different Trading Currencies
MA is traded in USD, while GSK.L is traded in GBp. To make them comparable, the GSK.L values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, MA achieves a -14.65% return, which is significantly lower than GSK.L's 5.71% return. Over the past 10 years, MA has outperformed GSK.L with an annualized return of 18.40%, while GSK.L has yielded a comparatively lower 4.80% annualized return.
MA
- 1D
- -1.10%
- 1M
- -1.98%
- YTD
- -14.65%
- 6M
- -9.84%
- 1Y
- -17.21%
- 3Y*
- 10.21%
- 5Y*
- 6.59%
- 10Y*
- 18.40%
GSK.L
- 1D
- -1.24%
- 1M
- 2.51%
- YTD
- 5.71%
- 6M
- 7.01%
- 1Y
- 29.39%
- 3Y*
- 18.35%
- 5Y*
- 4.98%
- 10Y*
- 4.80%
MA vs. GSK.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
MA Mastercard Incorporated | -14.65% | 9.04% | 24.17% | 23.40% | -2.66% | 1.16% | 20.19% | 59.16% | 25.31% | 47.69% |
GSK.L GlaxoSmithKline plc | 5.71% | 52.14% | -5.11% | 10.47% | -33.85% | 25.52% | -18.33% | 30.34% | 12.28% | -2.33% |
Correlation
The correlation between MA and GSK.L is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.18 |
Correlation (All Time) Calculated using the full available price history since Jul 6, 2007 | 0.21 |
Fundamentals
MA:
$433.70B
GSK.L:
£77.94B
MA:
$17.28
GSK.L:
£1.42
MA:
28.11
GSK.L:
13.43
MA:
1.64
GSK.L:
0.30
MA:
12.90
GSK.L:
2.39
MA:
64.52
GSK.L:
4.37
MA:
$33.94B
GSK.L:
£32.78B
MA:
$26.70B
GSK.L:
£23.84B
MA:
$21.23B
GSK.L:
£11.56B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MA vs. GSK.L — Risk / Return Rank
MA
GSK.L
MA vs. GSK.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Mastercard Incorporated (MA) and GlaxoSmithKline plc (GSK.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| MA | GSK.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.92 | ||
| Sortino ratioReturn per unit of downside risk | -2.74 | ||
| Omega ratioGain probability vs. loss probability | 0.88 | 1.21 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | -0.83 | 1.58 | -2.41 |
| Martin ratioReturn relative to average drawdown | -1.68 | 3.69 | -5.38 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| MA | GSK.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.78 | 1.15 | -1.92 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.28 | 0.20 | +0.07 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.69 | 0.21 | +0.48 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.83 | 0.15 | +0.68 |
Drawdowns
MA vs. GSK.L - Drawdown Comparison
The maximum MA drawdown since its inception was -62.67%, which is greater than GSK.L's maximum drawdown of -51.16%. Use the drawdown chart below to compare losses from any high point for MA and GSK.L.
Loading charts...
Drawdown Indicators
| MA | GSK.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.67% | -51.16% | -11.51% |
Max Drawdown (1Y)Largest decline over 1 year | -20.91% | -18.53% | -2.38% |
Max Drawdown (3Y)Largest decline over 3 years | -20.91% | -29.30% | +8.39% |
Max Drawdown (5Y)Largest decline over 5 years | -28.25% | -51.16% | +22.91% |
Max Drawdown (10Y)Largest decline over 10 years | -41.00% | -51.16% | +10.16% |
Current DrawdownCurrent decline from peak | -18.55% | -15.20% | -3.35% |
Average DrawdownAverage peak-to-trough decline | -9.82% | -15.96% | +6.14% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.26% | 7.93% | +2.33% |
Volatility
MA vs. GSK.L - Volatility Comparison
Mastercard Incorporated (MA) has a higher volatility of 6.33% compared to GlaxoSmithKline plc (GSK.L) at 5.92%. This indicates that MA's price experiences larger fluctuations and is considered to be riskier than GSK.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MA | GSK.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.33% | 5.92% | +0.41% |
Volatility (6M)Calculated over the trailing 6-month period | 17.37% | 18.51% | -1.14% |
Volatility (1Y)Calculated over the trailing 1-year period | 22.28% | 25.56% | -3.28% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.99% | 24.76% | -0.77% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 26.93% | 22.99% | +3.94% |
Dividends
MA vs. GSK.L - Dividend Comparison
MA's dividend yield for the trailing twelve months is around 0.67%, less than GSK.L's 3.50% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK.L GlaxoSmithKline plc | 3.50% | 3.51% | 4.53% | 3.84% | 5.30% | 4.93% | 5.90% | 4.45% | 5.31% | 5.99% | 4.88% | 5.77% |
MA Mastercard Incorporated | 0.67% | 0.53% | 0.50% | 0.53% | 0.56% | 0.49% | 0.45% | 0.44% | 0.53% | 0.58% | 0.74% | 0.66% |
Financials
MA vs. GSK.L - Financials Comparison
This section allows you to compare key financial metrics between Mastercard Incorporated and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
MA vs. GSK.L - Profitability Comparison
MA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Mastercard Incorporated reported a gross profit of 4.91B and revenue of 8.40B. Therefore, the gross margin over that period was 58.4%.
GSK.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
MA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Mastercard Incorporated reported an operating income of 4.91B and revenue of 8.40B, resulting in an operating margin of 58.4%.
GSK.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
MA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Mastercard Incorporated reported a net income of 3.88B and revenue of 8.40B, resulting in a net margin of 46.2%.
GSK.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
MA and GSK.L have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for MA and GSK.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer